Synthesis and evaluation of highly selective quinazoline-2,4-dione

ligands for sphingosine-1-phosphate receptor 2

Zonghua Luo,^{a,e} Hui Liu,^a Yanbo Yu,^a Robert. J. Gropler,^a Robyn S. Klein,^{b,c,d}, Zhude Tu*^a

^a Department of Radiology, Washington University School of Medicine, St. Louis, MO 63110, USA

^b Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA

^c Department of Neuroscience, Washington University School of Medicine, St. Louis, MO 63110, USA

^d Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA

^e School of Biomedical Engineering, ShanghaiTech University, Shanghai, 201210, China

Supplementary data

1.	The experimental section	2-9
2.	NMR spectra of target compounds	.10-38
3.	HRMS spectra of target compounds	39-53

Experimental

Chemistry

All the commercially available materials and solvents were obtained from Sigma-Aldrich and Fisher Scientific without further purification. Reactions were monitored by thin-layer chromatography (TLC) using fluorescent silica gel plates (60 F₂₅₄ from EMD Chemicals Inc.) and visualized under ultraviolet light (wavelength 254). Chromatographic purifications were performed by flash column chromatography using 230–400 mesh silica gel purchased from Silicycle. Yields refer to isolate yield and melting points were measured by MEL-TEMP 3.0 melting point apparatus without correction. ¹H NMR and ¹³C NMR spectra were recorded on Varian 400 MHz instrument, are reported in ppm using the solvent residual peak as an internal standard. High-resolution positive ion mass (HRMS) analyses were conducted on a Bruker MaXis 4G Q-TOF mass spectrometer with electrospray ionization source.

General method for the syntheses of 2a-k

A mixture of 2-(1-(2-((5-chloro-2,4-dimethoxyphenyl)amino)-2-oxoethyl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl)acetic acid (1) (1.0 eq),²⁷ HATU (1.5 eq), DIPEA (2.5 eq), and dimethyl sulfoxide (15 mL/mmol) was stirred for 5 min before adding the amines (1.1 eq). The reaction mixture was stirred at RT overnight and monitored by TLC. Upon the reaction was completed, the mixture was treated with water and the precipitate was filtered. The solid product was further washed with water and cold ethanol, then dried under vacuum.

N-(5-chloro-2,4-dimethoxyphenyl)-2-(3-(2-((2-hydroxyethyl)-amino)-2-oxoethyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)acetamide (2a). Following the general method, compound 2a was obtained from compound 1 and

ethanolamine as white solid. Yield: 77%, mp: 284-286 °C. ¹H NMR (400 MHz, DMSO-*d6*) δ 9.72 (s, 1H), 8.22 – 8.14 (m, 1H), 8.08 (d, *J* = 7.8 Hz, 1H), 7.91 (s, 1H), 7.78 (t, *J* = 7.8 Hz, 1H), 7.42 – 7.30 (m, 2H), 6.87 (s, 1H), 5.06 (s, 2H), 4.71 (t, *J* = 5.3 Hz, 1H), 4.58 (s, 2H), 3.92 (s, 3H), 3.88 (s, 3H), 3.46 – 3.37 (m, 2H), 3.21 – 3.10 (m, 2H). ¹³C NMR (101 MHz, DMSO-*d6*) δ 166.83, 166.01, 161.33, 152.00, 150.91, 150.28, 140.65, 135.89, 128.33, 123.46, 123.26, 120.65, 115.10, 115.05, 111.40, 98.42, 60.19, 56.81, 46.69, 46.18, 43.89, 42.03. HRMS (ESI) m/z [M+H]⁺ Calcd for C₂₂H₂₄ClN₄O₇ 491.1328, found 491.1330.

N-(5-chloro-2,4-dimethoxyphenyl)-2-(3-(2-((2-(2-hydroxy-ethoxy)ethyl)amino)-2-oxoethyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2*H*)-yl)acetamide (2*b*). Following the general method, compound 2*b* was obtained from compound 1 and 2-(2-aminoethoxy)ethanol as white solid. Yield: 55%, mp: 260-261 °C. ¹H NMR (400 MHz, DMSO-*d6*) δ 9.68 (s, 1H), 8.18 (t, *J* = 5.4 Hz, 1H), 8.04 (d, *J* = 6.7 Hz, 1H), 7.87 (s, 1H), 7.75 (t, *J* = 7.9 Hz, 1H), 7.37 – 7.27 (m, 2H), 6.84 (s, 1H), 5.02 (s, 2H), 4.56 – 4.51 (m, 3H), 3.89 (s, 3H), 3.84 (s, 3H), 3.51 – 3.44 (m, 2H), 3.43 – 3.36 (m, 3H), 3.25 – 3.16 (m, 2H). ¹³C NMR (101 MHz, DMSO-*d6*) δ 166.83, 166.00, 161.32, 151.98, 150.89, 150.26, 140.64, 135.90, 128.32, 123.47, 123.22, 120.63, 115.11, 115.03, 111.38, 98.40, 72.60, 69.39, 60.60, 56.82, 56.77, 46.68, 43.85, 39.24. HRMS (ESI) m/z [M+H]⁺ Calcd for C₂₄H₂₈ClN₄O₈ 535.1599, found 535.1597.

N-(5-chloro-2,4-dimethoxyphenyl)-2-(3-(2-((2-(2-(2-hydroxy-ethoxy)ethoxy)ethyl)amino)-2-oxoethyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2*H*)-yl)acetamide (2c). Following the general method, compound 2c was obtained from compound 1 and 2-[2-(2-aminoethoxy)ethoxy]ethanol as white solid. Yield: 34%, mp: 200-201 °C. ¹H NMR (400 MHz, DMSO-*d6*) δ 9.67 (s, 1H), 8.19 (t, *J* = 5.5 Hz, 1H), 8.04 (d, *J* = 7.8 Hz, 1H), 7.87 (s, 1H), 7.75 (t, *J* = 7.2 Hz, 1H), 7.39 – 7.26 (m, 2H), 6.84 (s, 1H), 5.02 (s, 2H), 4.58 – 4.48 (m, 3H), 3.89 (s, 3H), 3.84 (s, 3H), 3.52 – 3.49 (m, 3H), 3.48 – 3.43 (m, 2H), 3.42 – 3.35 (m, 4H), 3.24 – 3.16 (m, 2H). ¹³C NMR (101 MHz, DMSO-*d6*) δ 166.85, 165.99, 161.31, 151.97, 150.88, 150.26, 140.63, 135.90, 128.32, 123.46, 123.22, 120.62, 115.11, 115.03, 111.36, 98.39, 72.77, 70.11, 70.08, 69.44, 60.63, 56.82, 56.77, 46.67, 43.85, 39.19. HRMS (ESI) m/z [M+H]⁺ Calcd for C₂₆H₃₂ClN₄O₉ 579.1852, found 579.1853.

N-(5-chloro-2,4-dimethoxyphenyl)-2-(3-(2-(methylamino)-2-oxoethyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-

yl)acet-amide (2d). Following the general method, compound **2d** was obtained from compound **1** and methylamine as white solid. Yield: 56%, mp: 307-309 °C. ¹H NMR (400 MHz, DMSO-*d6*) δ 9.72 (s, 1H), 8.11 – 8.03 (m, 2H), 7.91 (s, 1H), 7.78 (t, *J* = 7.6 Hz, 1H), 7.41 – 7.30 (m, 2H), 6.87 (s, 1H), 5.06 (s, 2H), 4.54 (s, 2H), 3.92 (s, 3H), 3.88 (s, 3H), 2.60 (d, *J* = 4.5 Hz, 3H). ¹³C NMR (101 MHz, DMSO-*d6*) δ 167.18, 166.02, 161.37, 152.00, 150.91, 150.29, 140.67, 135.89, 128.32, 123.46, 123.26, 120.62, 115.12, 111.38, 98.40, 56.83, 56.78, 46.72, 43.98, 25.94. HRMS (ESI) m/z [M+H]⁺ Calcd for C₂₁H₂₂ClN₄O₆ 461.1222, found 461.1225.

2-(1-(2-((5-chloro-2,4-dimethoxyphenyl)amino)-2-oxoethyl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl)-N,N-

dimethylacet-amide (2e). Following the general method, compound **2e** was obtained from compound **1** and dimethylamine as white solid. Yield: 46%, mp: 253-255 °C. ¹H NMR (400 MHz, DMSO-*d6*) δ 9.74 (s, 1H), 8.07 (d, *J* = 7.4 Hz, 1H), 7.93 (s, 1H), 7.78 (t, *J* = 7.7 Hz, 1H), 7.43 – 7.29 (m, 2H), 6.87 (s, 1H), 5.07 (s, 2H), 4.81 (s, 2H), 3.93 (s, 3H), 3.88 (s, 3H), 3.09 (s, 3H), 2.85 (s, 3H). ¹³C NMR (101 MHz, DMSO-*d6*) δ 166.08, 165.95, 161.26, 151.94, 150.85, 150.18, 140.62,

135.95, 128.32, 123.51, 123.10, 120.72, 115.13, 114.91, 111.41, 98.42, 56.86, 56.77, 46.60, 42.99, 36.22, 35.53. HRMS (ESI) m/z [M+H]⁺ Calcd for $C_{22}H_{24}CIN_4O_6$ 475.1379, found 475.1378.

N-(5-chloro-2,4-dimethoxyphenyl)-2-(2,4-dioxo-3-(2-oxo-2-((2-(pyridin-3-yl)ethyl)amino)ethyl)-3,4-dihydro-

quinazolin-1(2*H***)-yl)acetamide (2f)**. Following the general method, compound **2f** was obtained from compound **1** and 2-(pyridin-3-yl)ethan-1-amine as white solid. Yield: 55%, mp: 248-249 °C. ¹H NMR (400 MHz, DMSO-*d*6) δ 9.73 (s, 1H), 8.49 – 8.38 (m, 2H), 8.28 (s, 1H), 8.09 (d, *J* = 7.5 Hz, 1H), 7.92 (s, 1H), 7.78 (d, *J* = 7.3 Hz, 1H), 7.64 (d, *J* = 7.1 Hz, 1H), 7.44 – 7.28 (m, 3H), 6.88 (s, 1H), 5.07 (s, 2H), 4.55 (s, 2H), 3.93 (s, 3H), 3.88 (s, 3H), 3.33 – 3.27 (m, 2H), 2.79 – 2.69 (m, 2H). ¹³C NMR (101 MHz, DMSO-*d*6) δ 166.84, 166.02, 161.35, 152.01, 150.91, 150.30, 147.85, 140.66, 136.72, 135.89, 135.28, 128.34, 123.84, 123.47, 123.28, 123.26, 120.65, 115.10, 111.41, 98.43, 56.86, 56.77, 46.71, 43.96, 40.37, 32.49. HRMS (ESI) m/z [M+H]⁺ Calcd for C₂₇H₂₇CIN₅O₆ 552.1644, found 552.1647.

N-(5-chloro-2,4-dimethoxyphenyl)-2-(3-(2-((2-methoxy-phenyl)amino)-2-oxoethyl)-2,4-dioxo-3,4-dihydroquinazolin-1(*2H*)-yl)acetamide (2g). Following the general method, compound 2g was obtained from compound 1 and *o*-anisidine as white solid. Yield: 52%, mp: 274-276 °C. ¹H NMR (400 MHz, DMSO-*d6*) δ 9.74 (s, 1H), 9.62 (s, 1H), 8.09 (d, *J* = 7.7 Hz, 1H), 7.98 – 7.88 (m, 2H), 7.84 – 7.75 (m, 1H), 7.45 – 7.29 (m, 2H), 7.10 – 7.01 (m, 2H), 6.92 – 6.82 (m, 2H), 5.08 (s, 2H), 4.88 (s, 2H), 3.92 (s, 3H), 3.87 (s, 6H). ¹³C NMR (101 MHz, DMSO-*d6*) δ 165.98, 165.78, 161.36, 151.98, 150.93, 150.25, 149.71, 140.65, 136.02, 128.37, 127.44, 124.80, 123.57, 123.18, 121.84, 120.68 (2C), 115.18, 114.92, 111.64, 111.41, 98.43, 56.87, 56.77, 56.12, 46.68, 44.62. HRMS (ESI) m/z [M+H]⁺ Calcd. for C₂₇H₂₆ClN₄O₇ 553.1485, found 553.1490.

N-(5-chloro-2,4-dimethoxyphenyl)-2-(3-(2-((3-methoxyphenyl)amino)-2-oxoethyl)-2,4-dioxo-3,4-dihydro-quinazolin-1(*2H*)-yl)acetamide (2h). Following the general method, compound 2h was obtained from compound 1 and *m*-anisidine as white solid. Yield: 54%, mp: 257-258 °C. ¹H NMR (400 MHz, DMSO-*d*6) δ 10.32 (s, 1H), 9.74 (s, 1H), 8.10 (d, *J* = 7.1 Hz, 1H), 7.93 (s, 1H), 7.80 (t, *J* = 7.3 Hz, 1H), 7.41 (d, *J* = 8.7 Hz, 1H), 7.35 (t, *J* = 7.6 Hz, 1H), 7.30 (s, 1H), 7.22 (t, *J* = 8.2 Hz, 1H), 7.09 (d, *J* = 8.1 Hz, 1H), 6.87 (s, 1H), 6.64 (d, *J* = 7.8 Hz, 1H), 5.09 (s, 2H), 4.79 (s, 2H), 3.92 (s, 3H), 3.88 (s, 3H), 3.72 (s, 3H). ¹³C NMR (101 MHz, DMSO-*d*6) δ 165.96, 165.64, 161.36, 159.97, 151.98, 150.92, 150.24, 140.65, 140.35, 136.05, 130.04, 128.37, 123.60, 123.20, 120.67, 115.21, 114.92, 111.65, 111.41, 109.44, 105.08, 98.42, 56.86, 56.76, 55.35, 46.70, 44.54. HRMS (ESI) m/z [M+H]⁺ Calcd for C₂₇H₂₆ClN₄O₇ 553.1485, found 553.1491.

N-(5-chloro-2,4-dimethoxyphenyl)-2-(3-(2-((4-methoxy-phenyl)amino)-2-oxoethyl)-2,4-dioxo-3,4-dihydroquinazolin-1(*2H*)-yl)acetamide (2i). Following the general method, compound 2i was obtained from compound 1 and *p*-anisidine as white solid. Yield: 16%, mp: 284-286 °C. ¹H NMR (400 MHz, DMSO-*d*6) δ 10.11 (s, 1H), 9.69 (s, 1H), 8.05 (d, *J* = 7.8 Hz, 1H), 7.88 (s, 1H), 7.76 (t, *J* = 7.8 Hz, 1H), 7.43 (d, *J* = 8.7 Hz, 2H), 7.38 – 7.28 (m, 2H), 6.88 – 6.81 (m, 3H), 5.04 (s, 2H), 4.71 (s, 2H), 3.88 (s, 3H), 3.84 (s, 3H), 3.68 (s, 3H). ¹³C NMR (101 MHz, DMSO-*d*6) δ 165.95, 165.05, 161.36, 155.66, 151.96, 150.92, 150.22, 140.64, 136.01, 132.30, 128.35, 123.56, 123.17, 120.96, 120.65, 115.18, 114.94, 114.32, 111.37, 98.39, 56.82, 56.77, 55.55, 46.68, 44.39. HRMS (ESI) m/z [M+H]⁺ Calcd for C₂₇H₂₆ClN₄O₇ 553.1485, found 553.1490. *N*-(5-chloro-2,4-dimethoxyphenyl)-2-(3-(2-((2-hydroxyphenyl)amino)-2-oxoethyl)-2,4-dioxo-3,4-dihydroquinazolin-

1(2H)-yl)acetamide (2j). Following the general method, compound **2j** was obtained from compound **1** and 3aminophenol as white solid. Yield: 62%, mp: 288-290 °C. ¹H NMR (400 MHz, DMSO-*d*6) δ 10.17 (s, 1H), 9.74 (s, 1H), 9.39 (s, 1H), 8.10 (d, *J* = 7.8 Hz, 1H), 7.93 (s, 1H), 7.80 (t, *J* = 7.6 Hz, 1H), 7.40 (d, *J* = 8.5 Hz, 1H), 7.35 (t, *J* = 7.6 Hz, 1H), 7.14 – 7.03 (m, 2H), 6.95 (d, *J* = 8.5 Hz, 1H), 6.87 (s, 1H), 6.46 (d, *J* = 8.0 Hz, 1H), 5.09 (s, 2H), 4.76 (s, 2H), 3.92 (s, 3H), 3.88 (s, 3H). ¹³C NMR (101 MHz, DMSO-*d*6) δ 165.96, 165.39, 161.36, 158.07, 151.98, 150.92, 150.25, 140.65, 140.17, 136.02, 129.88, 128.37, 123.58, 123.17, 120.68, 115.20, 114.94, 111.41, 110.95, 110.21, 106.66, 98.43, 56.86, 56.77, 46.69, 44.53. HRMS (ESI) m/z [M+H]⁺ Calcd for C₂₆H₂₄ClN₄O₇ 539.1328, found 539.1334.

N-(5-chloro-2,4-dimethoxyphenyl)-2-(3-(2-((4-hydroxy-phenyl)amino)-2-oxoethyl)-2,4-dioxo-3,4-dihydroquinazolin-

1(2*H***)-yl)acetamide (2k)**. Following the general method, compound **2k** was obtained from compound **1** and 4-aminophenol as white solid. Yield: 24%, mp: 319-321 °C. ¹H NMR (400 MHz, DMSO-*d6*) δ 9.98 (s, 1H), 9.70 (s, 1H), 9.16 (s, 1H), 8.06 (d, *J* = 7.3 Hz, 1H), 7.88 (s, 1H), 7.76 (t, *J* = 7.4 Hz, 1H), 7.39 – 7.32 (m, 1H), 7.30 (d, *J* = 8.5 Hz, 2H), 6.84 (s, 1H), 6.65 (d, *J* = 8.8 Hz, 2H), 5.04 (s, 2H), 4.70 (s, 2H), 3.89 (s, 3H), 3.84 (s, 3H). ¹³C NMR (101 MHz, DMSO-*d6*) δ 165.96, 164.82, 161.36, 153.78, 151.95, 150.91, 150.22, 140.64, 135.99, 130.80, 128.34, 123.55, 123.17, 121.19, 120.63, 115.53, 115.18, 114.95, 111.35, 98.38, 56.81, 56.77, 46.67, 44.35. HRMS (ESI) m/z [M+H]⁺ Calcd for C₂₆H₂₄ClN₄O₇ 539.1328, found 539.1331.

2-(2,4-Dioxo-1,4-dihydroquinazolin-3(2H)-yl)-N-(2-methoxyphenyl)acetamide (4)

A mixture of 2-(2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl)acetic acid (**3**)³⁰ (1.10 g, 5.0 mmol), *o*-anisidine (0.68 g, 5.5 mmol), HATU (2.85 g, 7.5 mmol), DIPEA (1.61 g, 12.5 mmol), and dichloromethane (40 mL) was stirred at room temperature. The reaction was stirred at room temperature overnight until the reaction was completed as determined by TLC. Then, the mixture was concentrated under vacuum. To the residue was added 1N HCl and the mixture was

stirred for 30 min at room temperature. The solid was filtered and dried as white solid. (1.4 g, 85%). ¹H NMR (400 MHz, DMSO-*d6*) δ 11.54 (s, 1H), 9.59 (s, 1H), 7.93 (dd, *J* = 12.9, 7.9 Hz, 2H), 7.74 – 7.67 (m, 1H), 7.24 (t, *J* = 7.9 Hz, 2H), 7.07 (d, *J* = 3.1 Hz, 2H), 6.93 – 6.86 (m, 1H), 4.80 (s, 2H), 3.87 (s, 3H).

General method for the syntheses of 5a-h

To a round-bottomed flask equipped with a magnetic stir bar were added **4** (1.0 eq), bromides (1.1 eq), K_2CO_3 (2.0 eq), and DMF (6.0 mL/mmol). The reaction was stirred at room temperature overnight until the reaction was completed as determined by TLC. Then, the reaction mixture was treated with water, the precipitate was filtered and washed with cold ethanol. The collected solid was dried under air.

N-(5-chloro-2-methoxyphenyl)-2-(3-(2-((2-methoxyphenyl)amino)-2-oxoethyl)-2,4-dioxo-3,4-dihydro-quinazolin-

1(2*H***)-yl)acetamide (5a)**. Following the general method, compound **5a** was obtained from compound **4** and 2-bromo-*N*-(5-chloro-2-methoxyphenyl)acetamide as white solid. Yield: 76%, mp: 218-219 °C. ¹H NMR (400 MHz, DMSO-*d*6) δ 9.88 (s, 1H), 9.60 (s, 1H), 8.05-8.10 (m, 2H), 7.90 (d, *J* = 7.4 Hz, 1H), 7.76 (t, *J* = 7.9 Hz, 1H), 7.39 (d, *J* = 8.4 Hz, 1H), 7.32 (t, *J* = 7.6 Hz, 1H), 7.21 – 6.98 (m, 4H), 6.86 (s, 1H), 5.12 (s, 2H), 4.85 (s, 2H), 3.86 (d, *J* = 7.6 Hz, 6H). ¹³C NMR (101 MHz, DMSO-*d*6) δ 166.50, 165.76, 161.34, 150.92, 149.70, 148.36, 140.64, 136.05, 128.66, 128.40, 127.43, 124.79, 124.30, 124.09, 123.59, 121.84, 120.79, 120.67, 115.17, 114.89, 113.02, 111.62, 56.58, 56.13, 46.86, 44.62. HRMS (ESI) m/z [M+H]⁺ Calcd for C₂₆H₂₄ClN₄O₆ 523.1379, found 523.1381.

2-(1-(2-(4-Fluorophenyl)-2-oxoethyl)-2,4-dioxo-1,4-dihydro-quinazolin-3(2*H*)-yl)-*N*-(2-methoxyphenyl)acetamide (5b)

Following the general method, compound **5b** was obtained from compound **4** and 2-bromo-1-(4-fluorophenyl)ethan-1one as white solid. Yield: 37%, mp: 224-226 °C. ¹H NMR (400 MHz, DMSO-*d6*) δ 9.62 (s, 1H), 8.29 – 8.18 (m, 2H), 8.12 (d, *J* = 8.1 Hz, 1H), 7.93 (d, *J* = 7.2 Hz, 1H), 7.73 (t, *J* = 7.7 Hz, 1H), 7.51 – 7.31 (m, 4H), 7.06 (s, 2H), 6.88 (s, 1H), 5.81 (s, 2H), 4.87 (s, 2H), 3.86 (s, 3H). ¹³C NMR (101 MHz, DMSO-*d6*) δ 192.06, 166.01 (d, *J* = 166.0 Hz), 165.73, 161.35, 150.84, 149.67, 140.57, 136.04, 131.85 (d, *J* = 10.1 Hz, 2C), 131.54 (d, *J* = 3.0 Hz), 128.46, 127.42, 124.77, 123.62, 121.80, 120.66, 116.46 (d, *J* = 22.2 Hz, 2C), 115.31, 114.88, 111.61, 56.12, 50.52, 44.60. HRMS (ESI) m/z [M+H]⁺ Calcd for C₂₅H₂₁FN₃O₅ 462.1460, found 462.1460.

N-(2-Methoxyphenyl)-2-(1-(2-(2-methoxyphenyl)-2-oxoethyl)-2,4-dioxo-1,4-dihydroquinazolin-3(2*H*)-yl)acetamide (5c)

Following the general method, compound **5c** was obtained from compound **4** and 2-bromo-1-(2-methoxyphenyl)ethan-1-one as white solid. Yield: 59%, mp: 252-254 °C. ¹H NMR (400 MHz, DMSO-*d*6) δ 9.61 (s, 1H), 8.11 (d, *J* = 7.6 Hz, 1H), 7.93 (d, *J* = 8.0 Hz, 1H), 7.80 – 7.65 (m, 3H), 7.37 – 7.24 (m, 3H), 7.11 (t, *J* = 7.4 Hz, 1H), 7.06 (s, 2H), 6.88 (s, 1H), 5.59 (s, 2H), 4.87 (s, 2H), 4.02 (s, 3H), 3.87 (s, 3H). ¹³C NMR (101 MHz, DMSO-*d*6) δ 193.44, 165.75, 161.37, 160.08, 150.86, 149.66, 140.50, 136.03, 135.87, 130.58, 128.39, 127.43, 124.77, 124.65, 123.51, 121.80, 121.20, 120.66, 115.31, 114.81, 113.26, 111.60, 56.51, 56.11, 54.29, 44.57. HRMS (ESI) m/z [M+H]⁺ Calcd for C₂₆H₂₄N₃O₆ 474.1660, found 474.1661.

N-(2,6-dichloropyridin-4-yl)-2-(3-(2-((2-methoxyphenyl)-amino)-2-oxoethyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2*H*)yl)acetamide (5d). Following the general method, compound 5d was obtained from compound 4 and 2-bromo-*N*-(2,6dichloropyridin-4-yl)acetamide as white solid. Yield: 82%, mp: 298-300 °C. ¹H NMR (400 MHz, DMSO-*d*6) δ 11.25 (s, 1H), 9.62 (s, 1H), 8.11 (d, *J* = 7.8 Hz, 1H), 7.92 (d, *J* = 7.8 Hz, 1H), 7.79 (t, *J* = 7.9 Hz, 1H), 7.63 (s, 2H), 7.48 (d, *J* = 8.5 Hz, 1H), 7.36 (t, *J* = 7.5 Hz, 1H), 7.06 (s, 2H), 6.93 – 6.84 (m, 1H), 5.07 (s, 2H), 4.87 (s, 2H), 3.87 (s, 3H). ¹³C NMR (101 MHz, DMSO*d*6) δ 167.77, 165.66, 161.27, 150.89, 150.28, 150.09, 149.66, 140.50, 136.06, 128.43, 127.38, 124.79, 123.74, 121.80, 120.65, 115.28, 114.86, 112.35, 111.60, 56.11, 47.16, 44.59. HRMS (ESI) m/z [M+H]⁺ Calcd for C₂₄H₂₀Cl₂N₅O₅ 528.0836, found 528.0838.

2-(1-(4-Fluorobenzyl)-2,4-dioxo-1,4-dihydroquinazolin-3(2*H***)-yl)-***N***-(2-methoxyphenyl)acetamide (5e). Following the general method, compound 5e** was obtained from compound **4** and 4-fluorobenzyl bromide as white solid. Yield: 51%, mp: 203-204 °C. ¹H NMR (400 MHz, DMSO-*d6*) δ 9.66 (s, 1H), 8.09 (d, *J* = 7.8 Hz, 1H), 7.92 (d, *J* = 8.0 Hz, 1H), 7.71 (t, *J* = 7.8 Hz, 1H), 7.40 – 7.27 (m, 4H), 7.17 (t, *J* = 8.8 Hz, 2H), 7.07 (s, 2H), 6.93 – 6.86 (m, 1H), 5.39 (s, 2H), 4.91 (s, 2H), 3.87 (s, 3H). ¹³C NMR (101 MHz, DMSO-*d6*) δ 165.93, 161.79 (d, *J* = 244.4 Hz, 1C), 161.36, 160.58, 151.20, 149.82, 139.87, 135.93, 132.76, 129.03 (d, *J* = 8.1 Hz, 2C), 128.57, 127.37, 124.87, 123.60, 122.08, 120.66, 115.93 (d, *J* = 21.2 Hz, 2C), 115.44 (d, *J* = 4.0 Hz, 1C), 111.65, 56.12, 45.98, 44.73. HRMS (ESI) m/z [M+H]⁺ Calcd for C₂₄H₂₁FN₃O₄ 434.1511, found 434.1510.

N-(2-methoxyphenyl)-2-(1-(2-(4-methoxyphenyl)-2-oxoethyl)-2,4-dioxo-1,4-dihydroquinazolin-3(2*H*)-yl)acetamide (5f).

Following the general method, compound **5f** was obtained from compound **4** and 2-bromo-4'-methoxyacetophenone as white solid. Yield: 76%, mp: 248-249 °C. ¹H NMR (400 MHz, DMSO-*d*6) δ 9.61 (s, 1H), 8.11 (d, *J* = 8.6 Hz, 3H), 7.93 (d,

J = 8.0 Hz, 1H), 7.73 (t, J = 7.9 Hz, 1H), 7.37 – 7.30 (m, 2H), 7.13 (d, J = 8.7 Hz, 2H), 7.06 (s, 2H), 6.92 – 6.84 (m, 1H), 5.75 (s, 2H), 4.87 (s, 2H), 3.87 (d, J = 9.5 Hz, 6H). ¹³C NMR (101 MHz, DMSO-*d6*) δ 191.53, 165.74, 164.30, 161.37, 150.86, 149.67, 140.65, 136.01, 131.07, 128.43, 127.69, 127.43, 124.77, 123.54, 121.80, 120.66, 115.31, 114.86, 114.59, 111.61, 56.12 (2C), 50.19, 44.59. HRMS (ESI) m/z [M+H]⁺ Calcd for C₂₆H₂₄N₃O₆ 474.160, found 474.1660.

2-(1-(2-(3-Chloro-4-methoxyphenyl)-2-oxoethyl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl)-N-(2-methoxyphenyl)-

acetamide (5g). Following the general method, compound **5g** was obtained from compound **4** and 2-bromo-1-(3-chloro-4-methoxyphenyl)ethan-1-one as white solid. Yield: 39%, mp: 257-259 °C. ¹H NMR (400 MHz, DMSO-*d*6) δ 9.62 (s, 1H), 8.20 (s, 1H), 8.16 – 8.07 (m, 2H), 7.94 (d, *J* = 7.9 Hz, 1H), 7.73 (t, *J* = 7.8 Hz, 1H), 7.42 – 7.30 (m, 3H), 7.13 – 7.04 (m, 2H), 6.95 – 6.85 (m, 1H), 5.78 (s, 2H), 4.88 (s, 2H), 3.99 (s, 3H), 3.86 (s, 3H). ¹³C NMR (101 MHz, DMSO-*d*6) δ 191.16, 165.73, 161.35, 159.40, 150.83, 149.68, 140.58, 136.03, 130.46, 129.84, 128.45, 128.26, 127.43, 124.78, 123.60, 122.02, 121.81, 120.67, 115.30, 114.88, 113.12, 111.62, 57.23, 56.16, 50.32, 44.60. HRMS (ESI) m/z [M+H]⁺ Calcd for C₂₆H₂₃ClN₃O₆ 508.1270, found 508.1274.

2-(1-(2-(3-chloro-4-ethoxyphenyl)-2-oxoethyl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl)-N-(2-

methoxyphenyl)acetamide (5h). Following the general method, compound 5h was obtained from compound 4 and 2-bromo-1-(3-chloro-4-ethoxyphenyl)ethan-1-one as white solid. Yield: 15%, mp: 227-228 °C. ¹H NMR (400 MHz, DMSO-*d*6) δ 9.58 (s, 1H), 8.16 (s, 1H), 8.07 (t, J = 7.9 Hz, 2H), 7.89 (d, J = 7.7 Hz, 1H), 7.73 – 7.66 (m, 1H), 7.37 – 7.27 (m, 3H), 7.02 (s, 2H), 6.89 – 6.82 (m, 1H), 5.74 (s, 2H), 4.83 (s, 2H), 4.31 – 4.20 (m, 2H), 3.83 (s, 3H), 1.37 (t, J = 6.7 Hz, 3H). ¹³C NMR (101 MHz, DMSO-*d*6) δ 191.12, 165.70, 161.33, 158.71, 150.81, 149.65, 140.57, 136.02, 130.51, 129.79, 128.43, 128.06, 127.41, 124.76, 123.58, 122.09, 121.79, 120.65, 115.30, 114.85, 113.74, 111.60, 65.44, 56.11, 50.30, 44.56, 14.79. HRMS (ESI) m/z [M+H]⁺ Calcd for C₂₇H₂₅ClN₃O₆ 522.1426, found 522.1428.

General method for the syntheses of 7a-e

To a round-bottomed flask equipped with a magnetic stir bar were added isatoic anhydride (1.0 eq), amines (1.0 eq), Et_3N (5.0 eq), and ethyl acetate (3.0 mL/mmol). The reaction mixture was stirred at 80 °C overnight until the reaction was completed as determined by TLC. After cooling to room temperature, the mixture was washed with 1 N NaOH (aqueous), saturated brine, and dried over anhydrous MgSO₄. After filtering and concentration, the crude product was obtained which was used directly for the next step.

To a round-bottomed flask equipped with a magnetic stir bar were added crude intermediates (1.0 eq), triphosgene (0.5 eq), and dichloromethane (5.0 mL/mmol). After 5 min, DIPEA (2.0 eq) was added dropwise and the mixture was stirred at room temperature for 3 h until the reaction was completed as determined by TLC. After removal of the solvent under vacuum, to the residue was added 1 N HCl and the mixture was stirred for 30 min at room temperature. The formed solid was filtered and washed with ethyl ether. After drying, the pure product was collected as white solid.

3-Benzylquinazoline-2,4(1*H***,3***H***)-dione (7a). Following the general method, compound 7a was obtained from isatoic anhydride and benzylamine. Yield: 93%. ¹H NMR (400 MHz, CDCl₃) \delta 11.56 (s, 1H), 7.94 (d,** *J* **= 8.0 Hz, 1H), 7.67 (t,** *J* **= 7.6 Hz, 1H), 7.31 (d,** *J* **= 3.9 Hz, 3H), 7.21 (t,** *J* **= 8.1 Hz, 2H), 5.09 (s, 2H).**

3-(2-Fluoroethyl)quinazoline-2,4(1H,3H)-dione (7b). Following the general method, compound **7b** was obtained from isatoic anhydride and 2-fluoroethylamine hydrochloride. Yield: 37%. ¹H NMR (400 MHz, DMSO-*d6*) δ 10.79 (s, 1H), 8.47 (d, *J* = 8.0 Hz, 1H), 8.12 (t, *J* = 7.6 Hz, 1H), 7.78 – 7.64 (m, 2H), 5.17 (t, *J* = 5.5 Hz, 1H), 5.05 (t, *J* = 5.5 Hz, 1H), 4.82 (t, *J* = 5.5 Hz, 1H), 4.76 (t, *J* = 5.5 Hz, 1H).

3-Methylquinazoline-2,4(1*H***,3***H***)-dione (7c). Following the general method, compound 7c was obtained from isatoic anhydride and methylamine hydrochloride. Yield: 73%. ¹H NMR (400 MHz, DMSO-***d6***) \delta 11.44 (s, 1H), 7.91 (d,** *J* **= 7.9 Hz, 1H), 7.64 (t,** *J* **= 7.7 Hz, 1H), 7.24 – 7.11 (m, 2H), 3.25 (s, 3H).**

3-Ethylquinazoline-2,4(1H,3H)-dione (7d). Following the general method, compound **7d** was obtained from isatoic anhydride and ethylamine. Yield: 65%. ¹H NMR (400 MHz, CDCl₃) δ 10.23 (s, 1H), 8.14 (d, *J* = 7.9 Hz, 1H), 7.61 (t, *J* = 7.7 Hz, 1H), 7.23 (t, *J* = 7.6 Hz, 1H), 7.13 (d, *J* = 8.1 Hz, 1H), 4.17 (q, *J* = 7.1 Hz, 2H), 1.32 (t, *J* = 7.1 Hz, 3H).

N-cyclopentyl-4-(2,4-dioxo-1,4-dihydroquinazolin-3(2*H*)-yl)-butanamide (7e). Following the general method, compound 7e was obtained from isatoic anhydride and 4-amino-*N*-cyclopentylbutanamide. Yield: 86%. ¹H NMR (400 MHz, CDCl₃) δ 9.71 (s, 1H), 8.12 (d, *J* = 7.8 Hz, 1H), 7.61 (t, *J* = 7.7 Hz, 1H), 7.23 (t, *J* = 7.6 Hz, 1H), 7.13 (d, *J* = 8.2 Hz, 1H), 6.19 (d, *J* = 7.0 Hz, 1H), 4.25 – 4.10 (m, 3H), 2.26 (t, *J* = 7.0 Hz, 2H), 2.08 (p, *J* = 6.7 Hz, 2H), 2.01 – 1.90 (m, 2H), 1.74 – 1.65 (m, 2H), 1.63 – 1.53 (m, 2H), 1.48 – 1.35 (m, 2H).

General method for the syntheses of 8a-e or 9a-e

To a round-bottomed flask equipped with a magnetic stir bar were added **7a-e** (1.0 eq), 2-bromo-1-(3-chloro-4-ethoxyphenyl)ethan-1-one or 2-bromo-N-(5-chloro-2,4-dimethoxyphenyl)acetamide (1.2 eq), K_2CO_3 (2.0 eq), and DMF

(6.0 mL/mmol). The reaction was stirred at room temperature overnight until the reaction was completed as determined by TLC. Then, the reaction mixture was treated with water and the precipitate was filtered. The collected solid was washed with water and cold acetone as the white solid product.

3-Benzyl-1-(2-(3-chloro-4-ethoxyphenyl)-2-oxoethyl)-quinazoline-2,4(1*H***,3***H***)-dione (8a). Following the general method, compound 8a was obtained from 7a and 2-bromo-1-(3-chloro-4-ethoxyphenyl)ethan-1-one. Yield: 58%, mp: 196-197 °C. ¹H NMR (400 MHz, CDCl₃) \delta 8.27 (d,** *J* **= 7.9 Hz, 1H), 8.07 (d,** *J* **= 2.1 Hz, 1H), 7.93 (dd,** *J* **= 8.6, 2.1 Hz, 1H), 7.56 (t,** *J* **= 7.8 Hz, 1H), 7.51 (d,** *J* **= 7.1 Hz, 2H), 7.31 (t,** *J* **= 7.3 Hz, 2H), 7.26 – 7.21 (m, 2H), 6.99 (d,** *J* **= 8.7 Hz, 1H), 6.82 (d,** *J* **= 8.5 Hz, 1H), 5.53 (s, 2H), 5.29 (s, 2H), 4.22 (q,** *J* **= 6.9 Hz, 2H), 1.53 (t,** *J* **= 7.0 Hz, 3H). ¹³C NMR (101 MHz, DMSO-***d***6) \delta 191.23, 161.48, 158.72, 150.96, 140.57, 137.44, 135.98, 130.52, 129.81, 128.79, 128.50, 128.03, 127.91, 127.63, 123.54, 122.11, 115.22, 114.96, 113.71, 65.44, 50.37, 44.70, 14.79. HRMS (ESI) m/z [M+H]⁺ Calcd for C₂₅H₂₂ClN₂O₄ 449.1263, found 449.1264.**

1-(2-(3-Chloro-4-ethoxyphenyl)-2-oxoethyl)-3-(2-fluoroethyl)-quinazoline-2,4(1*H***,3***H***)-dione (8b). Following the general method, compound 8b was obtained from 7b and 2-bromo-1-(3-chloro-4-ethoxyphenyl)ethan-1-one. Yield: 38%, mp: 197-199 °C. ¹H NMR (400 MHz, DMSO-***d6***) \delta 8.19 (s, 1H), 8.10 (t,** *J* **= 6.9 Hz, 2H), 7.71 (t,** *J* **= 7.6 Hz, 1H), 7.40 – 7.29 (m, 3H), 5.77 (s, 2H), 4.75 – 4.66 (m, 1H), 4.64 – 4.56 (m, 1H), 4.39 – 4.21 (m, 4H), 1.41 (t,** *J* **= 6.8 Hz, 3H). ¹³C NMR (101 MHz, DMSO-***d6***) \delta 191.18, 161.54, 158.73, 150.85, 140.54, 135.95, 130.52, 129.80, 128.43, 128.04, 123.53, 122.12, 115.21, 114.92, 113.73, 81.10 (d,** *J* **= 166.7 Hz), 65.45, 50.29, 41.69 (d,** *J* **= 22.2 Hz), 14.79. HRMS (ESI) m/z [M+H]⁺ Calcd for C₂₀H₁₉ClFN₂O₄ 405.1012, found 405.1012.**

1-(2-(3-Chloro-4-ethoxyphenyl)-2-oxoethyl)-3-methylquinazoline-2,4(1*H***,3***H***)-dione (8c). Following the general method, compound 8c was obtained from 7c and 2-bromo-1-(3-chloro-4-ethoxyphenyl)ethan-1-one. Yield: 53%, mp: 182-184 °C. ¹H NMR (400 MHz, CDCl₃) \delta 8.26 (d,** *J* **= 7.9 Hz, 1H), 8.09 (d,** *J* **= 2.0 Hz, 1H), 7.96 (dd,** *J* **= 8.6, 2.0 Hz, 1H), 7.56 (t,** *J* **= 7.9 Hz, 1H), 7.26 – 7.22 (m, 1H), 7.02 (d,** *J* **= 8.6 Hz, 1H), 6.82 (d,** *J* **= 8.4 Hz, 1H), 5.55 (s, 2H), 4.23 (q,** *J* **= 7.0 Hz, 2H), 3.51 (s, 3H), 1.54 (t,** *J* **= 7.0 Hz, 3H). ¹³C NMR (101 MHz, DMSO-***d***6) \delta 191.28, 161.64, 158.71, 151.05, 140.41, 135.67, 130.49, 129.77, 128.28, 128.08, 123.34, 122.11, 115.05, 114.96, 113.73, 65.45, 50.23, 28.56, 14.79. HRMS (ESI) m/z [M+H]⁺ Calcd for C₁₉H₁₈ClN₂O₄ 373.0950, found 373.0949.**

1-(2-(3-Chloro-4-ethoxyphenyl)-2-oxoethyl)-3-ethyl-quinazoline-2,4(1*H***,3***H***)-dione (8d). Following the general method, compound 8d was obtained from 7d and 2-bromo-1-(3-chloro-4-ethoxyphenyl)ethan-1-one. Yield: 23%, mp: 180-182 °C. ¹H NMR (400 MHz, CDCl₃) \delta 8.26 (d,** *J* **= 7.8 Hz, 1H), 8.09 (d,** *J* **= 2.1 Hz, 1H), 7.96 (d,** *J* **= 8.6 Hz, 1H), 7.56 (t,** *J* **= 7.2 Hz, 1H), 7.26 – 7.20 (m, 1H), 7.02 (d,** *J* **= 8.6 Hz, 1H), 6.82 (d,** *J* **= 8.4 Hz, 1H), 5.54 (s, 2H), 4.26 – 4.14 (m, 4H), 1.53 (t,** *J* **= 6.1 Hz, 3H), 1.31 (t,** *J* **= 7.1 Hz, 3H). ¹³C NMR (101 MHz, DMSO-***d***6) \delta 191.30, 161.18, 158.71, 150.61, 140.50, 135.72, 130.50, 129.79, 128.31, 128.06, 123.36, 122.10, 115.09, 115.08, 113.73, 65.44, 50.19, 36.76, 14.80, 13.29. HRMS (ESI) m/z [M+H]⁺ Calcd for C₂₀H₂₀ClN₂O₄ 387.1106, found 387.1108.**

4-(1-(2-(3-Chloro-4-ethoxyphenyl)-2-oxoethyl)-2,4-dioxo-1,4-dihydroquinazolin-3(2*H*)-yl)-*N*-cyclopentylbutanamide (8e).

Following the general method, compound **8e** was obtained from **7e** and 2-bromo-1-(3-chloro-4-ethoxyphenyl)ethan-1one. Yield: 70%, mp: 250-251 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.26 (d, *J* = 7.6 Hz, 1H), 8.09 (s, 1H), 7.99 – 7.92 (m, 1H), 7.77 (d, *J* = 11.3 Hz, 1H), 7.58 (t, *J* = 7.4 Hz, 1H), 7.03 (d, *J* = 8.7 Hz, 1H), 6.84 (d, *J* = 8.5 Hz, 1H), 6.20 (s, 1H), 5.53 (s, 2H), 4.26 – 4.15 (m, 5H), 2.24 – 2.19 (m, 2H), 2.11 – 2.04 (m, 2H), 1.98 – 1.90 (m, 2H), 1.71 – 1.62 (m, 2H), 1.55 – 1.50 (m, 3H), 1.44 – 1.36 (m, 2H), 1.29 – 1.23 (m, 2H). ¹³C NMR (101 MHz, DMSO-*d*6) δ 191.29, 171.06, 161.40, 158.69, 150.78, 140.52, 135.72, 130.49, 129.78, 128.38, 128.06, 123.33, 122.09, 115.05, 113.72, 109.99, 65.43, 50.49, 50.20, 41.27, 33.36, 32.66, 24.18, 23.80, 14.78. HRMS (ESI) m/z [M+H]⁺ Calcd for C₂₇H₃₁ClN₃O₅ 512.1947, found 512.1946.

2-(3-Benzyl-2,4-dioxo-3,4-dihydroquinazolin-1(2*H*)-yl)-*N*-(5-chloro-2,4-dimethoxyphenyl)acetamide (9a).

Following the general method, compound **9a** was obtained from **7a** and 2-bromo-*N*-(5-chloro-2,4-dimethoxyphenyl)-acetamide. Yield: 52%, mp: 234-237 °C. ¹H NMR (400 MHz, DMSO-*d6*) δ 9.76 (s, 1H), 8.10 (d, *J* = 7.5 Hz, 1H), 7.88 (s, 1H), 7.78 (t, *J* = 7.7 Hz, 1H), 7.41 – 7.22 (m, 7H), 6.87 (s, 1H), 5.17 (s, 2H), 5.07 (s, 2H), 3.92 (s, 3H), 3.87 (s, 3H). ¹³C NMR (101 MHz, DMSO-*d6*) δ 166.06, 161.50, 152.00, 151.07, 150.31, 140.65, 137.46, 135.94, 128.77, 128.40, 127.93, 127.60, 123.47, 123.31, 120.59, 115.06, 115.01, 111.35, 98.37, 56.81, 56.75, 46.72, 44.73. HRMS (ESI) m/z [M+H]⁺ Calcd for C₂₅H₂₃ClN₃O₅ 480.1321, found 480.1324.

N-(5-Chloro-2,4-dimethoxyphenyl)-2-(3-(2-fluoroethyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2*H*)-yl)acetamide (9b).

Following the general method, compound **9b** was obtained from **7b** and 2-bromo-*N*-(5-chloro-2,4-dimethoxyphenyl)-acetamide. Yield: 50%, mp: 268-270 °C. ¹H NMR (400 MHz, DMSO-*d6*) δ 9.74 (s, 1H), 8.09 (d, *J* = 7.9 Hz, 1H), 7.89 (s, 1H), 7.78 (t, *J* = 7.9 Hz, 1H), 7.42 – 7.28 (m, 2H), 6.87 (s, 1H), 5.06 (s, 2H), 4.72 (t, *J* = 4.9 Hz, 1H), 4.60 (t, *J* = 4.9 Hz, 1H), 4.35 (t, *J* = 4.8 Hz, 1H), 4.29 (t, *J* = 4.7 Hz, 1H), 3.90 (d, *J* = 17.3 Hz, 6H). ¹³C NMR (101 MHz, DMSO-*d6*) δ 166.05, 161.58, 152.03, 150.96, 150.35, 140.61, 135.92, 128.35, 123.48, 123.36, 120.57, 115.07, 114.99, 111.37, 98.38, 81.12 (d, *J* = 4.9 Hz, 1H), 4.50 (d, J) = 4.50 (d, J) = 4

167.7 Hz, 1C), 56.82, 56.76, 46.69, 41.68 (d, J = 22.2 Hz, 1C). HRMS (ESI) m/z [M+H]⁺ Calcd for C₂₀H₂₀ClFN₃O₅ 436.1070, found 436.1073.

N-(5-Chloro-2,4-dimethoxyphenyl)-2-(3-methyl-2,4-dioxo-3,4-dihydroquinazolin-1(2*H*)-yl)acetamide (9c).

Following the general method, compound **9c** was obtained from **7c** and 2-bromo-*N*-(5-chloro-2,4-dimethoxyphenyl)acetamide. Yield: 74%, mp: 314-315 °C. ¹H NMR (400 MHz, DMSO-*d6*) δ 9.72 (s, 1H), 8.08 (d, *J* = 7.8 Hz, 1H), 7.87 (s, 1H), 7.75 (t, *J* = 7.9 Hz, 1H), 7.40 – 7.27 (m, 2H), 6.87 (s, 1H), 5.05 (s, 2H), 3.90 (d, *J* = 16.5 Hz, 6H), 3.34 (s, 3H). ¹³C NMR (101 MHz, DMSO-*d6*) δ 166.16, 161.71, 152.05, 151.18, 150.42, 140.49, 135.66, 128.21, 123.44, 123.31, 120.57, 115.05, 114.93, 111.36, 98.41, 56.83, 56.78, 46.65, 28.59. HRMS (ESI) m/z [M+H]⁺ Calcd for C₁₉H₁₉ClN₃O₅ 404.1008, found 404.1009.

N-(5-Chloro-2,4-dimethoxyphenyl)-2-(3-ethyl-2,4-dioxo-3,4-dihydroquinazolin-1(2*H*)-yl)acetamide (9d).

Following the general method, compound **9d** was obtained from **7d** and 2-bromo-*N*-(5-chloro-2,4-dimethoxyphenyl)-acetamide. Yield: 26%, mp: 263-264 °C. ¹H NMR (400 MHz, DMSO-*d6*) δ 9.69 (s, 1H), 8.04 (d, *J* = 7.8 Hz, 1H), 7.85 (s, 1H), 7.71 (t, *J* = 7.7 Hz, 1H), 7.35 – 7.24 (m, 2H), 6.82 (s, 1H), 4.99 (s, 2H), 3.97 (q, *J* = 7.0 Hz, 2H), 3.85 (d, *J* = 16.2 Hz, 6H), 1.14 (t, *J* = 7.0 Hz, 3H). ¹³C NMR (101 MHz, DMSO-*d6*) δ 166.14, 161.22, 151.98, 150.72, 150.34, 140.57, 135.67, 128.22, 123.33, 123.29, 120.63, 115.14, 114.93, 111.34, 98.38, 56.81, 56.76, 46.57, 36.76, 13.28. HRMS (ESI) m/z [M+H]⁺ Calcd for C₂₀H₂₁ClN₃O₅ 418.1164, found 418.1167.

4-(1-(2-((5-Chloro-2,4-dimethoxyphenyl)amino)-2-oxoethyl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl)-N-cyclo-

pentyl-butanamide (9e). Following the general method, compound **9e** was obtained from **7e** and 2-bromo-*N*-(5-chloro-2,4-dimethoxy-phenyl)acetamide. Yield: 52%, mp: 260-262 °C. ¹H NMR (400 MHz, DMSO-*d6*) δ 9.73 (s, 1H), 8.08 (d, *J* = 7.5 Hz, 1H), 7.86 (s, 1H), 7.80 – 7.70 (m, 2H), 7.40 – 7.27 (m, 2H), 6.87 (s, 1H), 5.04 (s, 2H), 4.02 – 3.83 (m, 9H), 2.08 (t, *J* = 7.5 Hz, 2H), 1.87 – 1.78 (m, 2H), 1.77 – 1.66 (m, 2H), 1.64 – 1.54 (m, 2H), 1.50 – 1.41 (m, 2H), 1.35 – 1.25 (m, 2H). ¹³C NMR (101 MHz, DMSO-*d6*) δ 171.16, 166.16, 161.47, 152.07, 150.92, 150.44, 140.58, 135.69, 128.32, 123.47, 123.29, 120.56, 115.16, 114.90, 111.37, 98.39, 56.83, 56.76, 50.52, 46.65, 41.32, 33.40, 32.67, 24.11, 23.82. HRMS (ESI) m/z [M+H]⁺ Calcd for C₂₇H₃₂CIN₄O₆ 543.2005, found 543.2004.

2-(2,4-Dioxo-1,4-dihydroquinazolin-3(2*H*)-yl)-*N*-(2-hydroxyethyl)-acetamide (10)

A mixture of 2-(2,4-dioxo-1,4-dihydroquinazolin-3(2*H*)-yl)acetic acid (**3**) (0.44 g, 2.0 mmol), ethanolamine (0.15 g, 2.4 mmol), HATU (1.14 g, 3.0 mmol), DIPEA (0.65 g, 5.0 mmol), and dichloromethane (15 mL) was stirred at room temperature. The reaction was stirred at room temperature overnight until the reaction was completed as determined by TLC. Then, the mixture was concentrated under vacuum. To the residue was added 1N HCl and the mixture was stirred for 30 min at room temperature. The solid was filtered and dried as white solid. (0.24 g, 46%). ¹H NMR (400 MHz, DMSO-*d6*) δ 11.41 (s, 1H), 8.13 (s, 1H), 7.92 (d, *J* = 7.3 Hz, 1H), 7.67 (t, *J* = 7.4 Hz, 1H), 7.21 (t, *J* = 8.2 Hz, 2H), 4.69 (s, 1H), 4.48 (s, 2H), 3.39 (s, 2H), 3.13 (s, 2H).

tert-Butyl 2-(3-(2-((2-hydroxyethyl)amino)-2-oxoethyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)acetate (11)

To a round-bottomed flask equipped with a magnetic stir bar were added **10** (0.60 g, 2.3 mmol), *tert*-butyl bromoacetate (0.47 g, 2.4 mmol), K_2CO_3 (138 mg, 2.0 eq), and DMF (10 mL). The reaction was stirred at room temperature overnight until the reaction was completed as determined by TLC. Then, the reaction mixture was diluted with ethyl acetate and washed with water and saturated brine. After drying over MgSO₄, the mixture was filtered and the filtrate was concentrated under vacuum. The residue was purified by flash chromatography with eluent of ethyl acetate (0.5 g, 58%).

2-(3-(2-((2-Hydroxyethyl)amino)-2-oxoethyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2*H*)-yl)acetic acid (12)

To a round-bottomed flask equipped with a magnetic stir bar were added **11** (0.50 g, 1.3 mmol), trifluoroacetic acid (5 mL), and dichloromethane (5 mL). The reaction was stirred at room temperature for 3 h until the reaction was completed as determined by TLC. Then, the reaction mixture was concentrated under vacuum to give white solid product (0.4 g, 96%). ¹H NMR (400 MHz, DMSO-*d*6) δ 8.41 (t, *J* = 5.3 Hz, 1H), 8.07 (d, *J* = 7.8 Hz, 1H), 7.78 (t, *J* = 7.8 Hz, 1H), 7.43 – 7.28 (m, 2H), 4.88 (s, 2H), 4.55 (s, 2H), 4.39 (t, *J* = 5.3 Hz, 2H), 3.49 – 3.38 (m, 3H).

N-(5-Chloro-4-hydroxy-2-methoxyphenyl)-2-(3-(2-((2-hydroxyethyl)amino)-2-oxoethyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2*H*)-yl)acetamide (13)

A mixture of **12** (96 mg, 0.30 mmol), 4-amino-2-chloro-5-methoxyphenol (57 mg, 0.33 mmol), HATU (171 mg, 0.45 mmol), DIPEA (97 mg, 0.75 mmol), and dimethyl sulfoxide (3 mL) was stirred at room temperature. The reaction was stirred at room temperature for overnight until the reaction was completed as determined by TLC. Then, the mixture was diluted with water and the precipitate was filtered and dried as white solid. (50 mg, 35%). ¹H NMR (400 MHz, DMSO-

d6) δ 10.04 (s, 1H), 9.61 (s, 1H), 8.16 (s, 1H), 8.07 (d, *J* = 8.0 Hz, 1H), 7.83 – 7.72 (m, 2H), 7.34 (dd, *J* = 16.4, 8.4 Hz, 2H), 6.66 (s, 1H), 5.03 (s, 2H), 4.69 (s, 1H), 4.57 (s, 2H), 3.80 (s, 3H), 3.40 (dd, *J* = 11.0, 5.4 Hz, 2H), 3.14 (dd, *J* = 11.5, 5.8 Hz, 2H).

Radiochemistry

 $[^{11}C]CO_2$ was produced via a $^{14}N(p,\alpha)^{11}C$ reaction with a 40 μ A beam of 16 MeV protons on a target of 0.5% O_2 in N_2 for 25 min with a JSW BC-16/8 cyclotron, and shunted to a GE PETtrace MeI Microlab to convert $[^{11}C]CH_3I$.

Radiosynthesis of [¹¹C]2a

 $[^{11}C]CH_3I$ was released with helium at a flow rate of 20 mL/min to a reaction vessel containing ~1.0 mg of precursor **13**, 2 µL of 5 M NaOH, and 300 µL of DMSO at room temperature. Once the radioactivity reached the maximum, the reaction mixture was heated at 90 °C for 5 min. After quenching with 1.5 mL of HPLC mobile phase (30% acetonitrile in 0.1 M ammonium formate buffer, pH = 4.5). The reactive mixture was loaded onto a semi-preparative C-18 column (Agilent SB-C18,250 x 9.6 mm, 5 µm), then eluted from the column using above mentioned HPLC mobile phase at a flow rate of 4.0 mL/min. The radioactive product fraction was collected to 50 mL of Milli-Q water, followed by trapping on a C18 Sep-Pak Plus cartridge. The C18 cartridge was further washed with 20 mL of Milli-Q water to remove the solvent residue. Then, the radioactive product was eluted out from the C18 cartridge with 0.6 mL of ethanol and 5.4 mL of 0.9% saline. Radiochemical purity was determined by analytical HPLC on a reverse-phase analytical column (Agilent SB-C18, 250 X 4.6 mm, 5 µm) with a mobile phase of 55% 0.1 M ammonium formate (pH 4.5) in acetonitrile and flow rate of 1.0 mL/min



(Figure S1).

Figure S1. The analytical HPLC trace of [¹¹C]2a

Radiosynthesis of [¹¹C]2i

[¹¹C]CH₃I was released with helium at a flow rate of 20 mL/min to a reaction vessel containing ~1.0 mg of precursor **2k**, 2 μ L of 5 M NaOH, and 300 μ L of DMSO at room temperature. Once the radioactivity reaches the maximum, the reaction mixture was heated at 90 °C for 5 min. After quenching with 1.5 mL of HPLC mobile phase (45% acetonitrile in 0.1 M ammonium formate buffer, pH = 4.5). The reactive mixture was loaded onto a semi-preparative C-18 column (Agilent SB-C18,250 x 9.6 mm, 5 μ m), then eluted from the column using above mentioned HPLC mobile phase at a flow rate of 4.0 mL/min. The radioactive product fraction was collected to 50 mL of Milli-Q water, followed by trapping on a C18 Sep-Pak Plus cartridge. The C18 cartridge was further washed with 20 mL of Milli-Q water to remove the solvent residue. Then, the radioactive product was eluted out from the C18 cartridge with 0.6 mL of ethanol and 5.4 mL of 5% Kolliphor[®] HS 15 solution. Radiochemical purity was determined by analytical HPLC on a reverse-phase analytical column (Agilent SB-C18, 250 X 4.6 mm, 5 μ m) with a mobile phase of 25% 0.1 M ammonium formate (pH 4.5) in acetonitrile and flow rate of 1.0 mL/min (Figure S2).



In vitro binding assay

The binding potency of newly synthesized compounds to S1PR2 was determined by a [³²P]S1P competitive binding assay according to our previously reported protocol²⁴. Briefly, increasing concentrations of compounds (0.01, 0.1, 1.0, 10, 100, and 1000 nM) were incubated with ChemiSCREEN[™] human recombinant S1PR2 lysophospholipid receptor membrane (Millipore, Billerica, MA) (~1 µg/well) and [³²P]S1P (0.1 nM) in a 96-well poly-L-lysine microplate for 60 min. The reaction was terminated by collecting the membranes onto 96-well glass fiber filtration plates (Millipore, Billerica, MA). After washing with cold assay buffer (50 mM HEPES Na, pH 7.5, 5 mM MgCl₂, 1 mM CaCl₂, and 0.5% fatty acid-free bovine serum albumin), the filter-bound radioactivity was measured by a Beckman LS 3801 scintillation counter using Cherenkov counting. The binding affinity of compounds toward the other four S1PRs was similarly determined using the above procedure. Human recombinant S1PR1, 2, 3, and 5 lysophospholipid receptor membranes were purchased from Muiltispan (Multispan, Hayward, CA). IC₅₀ values were calculated using GraphPad Prism (GraphPadSoftware, Inc., San Diego, CA).

Tissue distribution studies of [¹¹C]2a and [¹¹C]2i in rodents

Ex-vivo tissue distribution of [11C]2a

A solution of $[^{11}C]$ **2a** (~3.7 MBq/100 µL) in 10% ethanol in 0.9% saline was injected via the tail vein into adult male Sprague Dawley (SD) rats (n = 12, 8 weeks, 200-250 g, Charles River) under 2-3% isoflurane/oxygen anesthesia. The rats were euthanized under anesthesia at 5, 30, and 60 min post-injection (n = 4 for each group). Organs of blood, heart, lung, muscle, pancreas, spleen, kidney, liver, thymus, and brain were dissected and collected for counting. All the samples were counted with a dilution of the injectate on an automated well counter (Beckman Gamma 8000 well counter). Tissues were weighed and the uptake was reported as background and decay-corrected percent injected dose per gram (% ID/gram).

Ex-vivo tissue distribution of [11C]2i in SJL mice

The *ex-vivo* biodistribution study of $[^{11}C]$ **2i** in normal female SJL mice (8 weeks, 16-22 g) was performed using a similar experimental procedure as the study of $[^{11}C]$ **2a**.























































































